Short Reads

Premium

Apparently smoothing over past problems and threats of a lawsuit, Paradigm Genetics announced that former president and CEO John Ryals has left the company’s board of directors.

 

GPC Biotech fills up its clinical development stable in Princeton, NJ: Edward McNiff is VP of pharmaceutical development; Thomas McKearn is VP of medical affairs; Michael Petrone is VP of clinical operations; and John Slayback is director of analytical and formulation development and outsourcing.

 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.